0001209191-19-004547.txt : 20190118 0001209191-19-004547.hdr.sgml : 20190118 20190118161303 ACCESSION NUMBER: 0001209191-19-004547 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180323 FILED AS OF DATE: 20190118 DATE AS OF CHANGE: 20190118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Flynn Daniel Lee CENTRAL INDEX KEY: 0001713712 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 19533385 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC STREET 2: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-23 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001713712 Flynn Daniel Lee C/O DECIPHERA PHARMACEUTICALS, INC. 500 TOTTEN POND ROAD WALTHAM MA 02451 0 1 0 0 Chief Scientific Officer Common Stock 2018-03-23 5 G 0 E 91779 0.00 A 91779 I By Daniel L. Flynn Irrevocable Trust Common Stock 2018-03-23 5 G 0 E 91779 0.00 D 55270 I By Biochenomix, LLC Common Stock 2019-01-16 4 M 0 152629 1.89 A 152629 D Common Stock 2019-01-16 4 S 0 152629 26.00 D 0 D Stock Option (Right to Buy) 1.89 2019-01-16 4 M 0 152629 0.00 D 2025-12-17 Common Stock 152629 472678 D This transaction involved a transfer of shares to the Daniel L. Flynn Irrevocable Trust from Biochenomix, LLC. The Reporting Person's daughter is trustee of the trust and the Reporting Person's spouse is the sole lifetime beneficiary of the trust. The Reporting Person disclaims Section 16 beneficial ownership over all such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that the Reporting Person has beneficial ownership of such shares for Section 16 or for any other purposes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. /s/ Jeffrey M. Held, Attorney-in-Fact 2019-01-18